Menu Search
Equities

Alvotech SA

ALVO:ICX

Alvotech SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ISK)1,690.00
  • Today's Change10.00 / 0.60%
  • Shares traded372.24k
  • 1 Year change+30.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 16:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Alvotech SA had net income fall 7.43% from a loss of 513.58m to a larger loss of 551.73m despite a 9.84% increase in revenues from 85.02m to 93.38m. An increase in the cost of goods sold as a percentage of sales from 75.39% to 172.26% was a component in the falling net income despite rising revenues.
Gross margin48.79%
Net profit margin-200.30%
Operating margin-46.59%
Return on assets-62.49%
Return on equity--
Return on investment-222.85%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Alvotech SA fell by 55.27m. Cash Flow from Financing totalled 301.32m or 322.67% of revenues. In addition the company used 312.19m for operations while cash used for investing totalled 46.34m.
Cash flow per share-2.44
Price/Cash flow per share--
Book value per share-2.27
Tangible book value per share-2.39
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.